TCNNF Q3 FY26 earnings call: key takeaways

• Trulieve reported third quarter 2026 revenue of $230 million, which exceeded guidance and outperformed typical seasonal trends (17:34)
• The company highlighted significant benefits from the rescheduling of state-licensed medical marijuana, including DEA registration and tax parity (16:06)
• The main message of the call focused on growth opportunities in Georgia and Texas, as well as operational improvements. (14:48)

What changed since last quarter

• The company raised its outlook for the fourth quarter, expecting revenue to grow at low single digits compared to the third quarter. (31:24)
• Trulieve's CFO mentioned that the paid purchase accounting adjustments for the harvest deconsolidation will result in a net loss for the fourth quarter, impacting reported results. (31:24)
• The CEO emphasized the importance of federal rescheduling and the potential for broader cannabis reform, indicating a shift in focus towards policy advocacy. (14:48)

What analysts pressed on

• Whether the increase in demand in Georgia will create bottlenecks in the supply chain. (50:26)
• How the seasonal patterns in Florida will change with the growth of Georgia and Pennsylvania. (53:49)
• The potential impact of the DEA registration on compliance costs and wholesale operations. (57:42)

In their words

• We are the largest U.S. medical cannabis operator with 208 dispensaries and 3.5 million square feet of production capacity. (14:48)
• Trulieve listed its medical-only Schedule III business on the NYSE in June. (17:34)
• We are already scaling production and retail in Georgia to meet increased demand. Kim Rivers (35:50)